Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth



Merck soundly beat Wall Street estimates for its top and bottom lines, reporting earnings of $2.14 per share on $15.9 billion in revenue.



Source link

Leave a Reply

Your email address will not be published.

13 + seventeen =